MSB 2.17% $1.13 mesoblast limited

2023 The Final Countdown, page-1218

  1. 16,702 Posts.
    lightbulb Created with Sketch. 2381
    I don't think that the correct parallel is watching a disaster unfold if they were to make a conditional approval for Remestemcel. Except in the sense that the FDA would be making a political decision rather than a scientifically based one, which would undermine their standing as an unbiased regulator of medical therapy intended to safeguard Americans from unsafe or useless treatments.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.